Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

EMERYVILLE, Calif., March 28, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced its plans to expand the Phase 3 European clinical trial FOCUS, which is evaluating the efficacy and tolerability of carfilzomib, a selective next-generation proteasome inhibitor. The FOCUS trial is designed to support the registrational filing with the European Medicines Agency (EMA) in patients with relapsed and refractory myeloma.  

The FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple Myeloma European Study) trial modification includes two key enhancements to the study: changing the primary end point to overall survival (OS) from progression-free survival (PFS) and correspondingly increasing patient enrollment to 300 from 84.  These modifications are supported by overall survival data from the Phase 2b 003-A1 study evaluating single-agent carfilzomib in patients with relapsed and refractory multiple myeloma announced at the American Society of Hematology (ASH) meeting in December 2010.  The company expects to review these data with the EMA and is moving forward with plans to do so.

"Given the encouraging carfilzomib data reported to date, including the 003-A1 survival data, Onyx decided to make this change to demonstrate a potential mortality benefit for carfilzomib," said Ted Love, M.D., executive vice president, research and development and technical operations at Onyx.  "We plan to upsize the trial at the currently active sites by leveraging the momentum we are seeing in enrollment as well as by adding additional sites, as appropriate."

Focus Trial Design

As modified, the Phase 3 FOCUS study will be a randomized 300-patient trial evaluating carfilzomib versus best supportive care of low dose steroids plus cytoxan (optional), in patients with relapsed and refractory multip
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and ... free download , digs deep into this vibrant market, ... sector today. One area where Algeria ... a homegrown pharmaceutical manufacturing base, even if the government,s ambitious ... off. A cursory comparison with neighboring Morocco ...
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... Joseph,s Hospital and Medical Center, Phoenix, today announced that it ... videoconferencing system to connect specialist physicians at the ... will include the Barrow Neurological Institute, as well as other ... , With the objective of further enhancing patient ...
... 17 Senetek PLC,(OTC Bulletin Board: SNKTY), a Life ... the science of healthy aging, today,announced that shareholders have ... the Annual General Meeting of Shareholders held on,December 16, ... are pleased with the results of the voting and ...
... Zeller appointed Senior Director, Regulatory Affairs-- , ... Microbia Precision Engineering, Inc. (Microbia) announced today that it ... capabilities with the appointments of Gaye Bok as Senior ... Director of Regulatory Affairs. , , ...
Cached Biology Technology:St. Joseph's Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians 2St. Joseph's Hospital and Medical Center to Utilize Clinical InfoNET System for Physicians 3Senetek PLC Announces 2008 Annual General Meeting Voting Results 2Microbia PE Bolsters Senior Management Team; Positions Company for Commercializing Proprietary Bioproducts 2Microbia PE Bolsters Senior Management Team; Positions Company for Commercializing Proprietary Bioproducts 3
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM ... Practices (GCP) audit to confirm its adherence to ... This accomplishment enables HITLAB to conduct regulated smart ... highest principles for patient safety and research quality. ... healthcare access, quality, and delivery with innovative technology," ...
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... Magellanic penguins have a high level of variation in ... a recent study found that the mechanism the penguins use ... Found exclusively south of the equator in South America, ... of Argentina, Chile, and the Falkland Islands. They typically mate ...
... most prestigious scientific conferences at the Spanish National Cancer ... a double bill focusing on cancer genetics next Thursday ... June, with over 30 scientific talks of international excellence., ... Institute of Biochemistry (Germany), will give a talk next ...
... online and in print today a special issue dedicated to ... to characterize all functional elements in the human genome. ... in 2007, covering 1% of the genome, The ENCODE Consortium ... regulation on an unprecedented scale. This special issue presents ...
Cached Biology News:Picky penguins: Does mate choice depend on genes that help resist disease? 2Picky penguins: Does mate choice depend on genes that help resist disease? 3The CNIO welcomes the new academic year with a spotlight on cancer genetics 2The ENCODE Project publishes new genomic insights in special issue of Genome Research 2The ENCODE Project publishes new genomic insights in special issue of Genome Research 3The ENCODE Project publishes new genomic insights in special issue of Genome Research 4The ENCODE Project publishes new genomic insights in special issue of Genome Research 5The ENCODE Project publishes new genomic insights in special issue of Genome Research 6
... versatile enclosures are designed ... or other process gas ... environment. HEPA filtration, heating/cooling, ... modules also available, along ...
... researcher, the new 4300 DNA Analysis System from ... quality of your data. High confidence in more ... LI-COR DNA analysis systems have had for more ... third generation instrument based on LI-CORs highly sensitive ...
... isolation chamber provides a safe, clean ... pharmaceuticals, in accord with USP-797 requirements. ... (ISO 5) cleanliness conditions in the ... rod and tilt-up front panel for ...
... siRNA Tracker Intracellular Localization Kit with ... forward approach to directly label and ... an efficient yet non-destructive manner, for ... and functional inhibition of target gene ...
Biology Products: